Walgreens Boots Alliance, Inc. (WBA) Bundle
A Brief History of Walgreens Boots Alliance, Inc.
Walgreens Boots Alliance, Inc. (WBA) has undergone significant transformations and faced substantial challenges in recent years, particularly through fiscal 2024, culminating in various financial metrics and operational shifts.
Financial Performance Overview
For the fiscal year ending August 31, 2024, Walgreens Boots Alliance reported:
| Metric | 2024 | 2023 | 2022 |
|---|---|---|---|
| Sales (in millions) | $147,658 | $139,081 | $132,703 |
| Cost of Sales (in millions) | $121,134 | $112,009 | $104,437 |
| Gross Profit (in millions) | $26,524 | $27,072 | $28,265 |
| Selling, General and Administrative Expenses (in millions) | $28,113 | $34,205 | $27,295 |
| Net Loss (in millions) | $(8,636) | $(3,080) | $4,337 |
| Diluted Net Loss per Share | $(10.01) | $(3.57) | $5.01 |
Operational Highlights
In fiscal 2024, Walgreens Boots Alliance experienced a significant impairment charge of $12.7 billion related to goodwill, primarily attributed to its U.S. Healthcare segment. This was a substantial increase compared to previous years, reflecting ongoing challenges in integrating acquisitions and managing operational efficiency.
Sales growth was driven by strong performance in the U.S. retail pharmacy segment, generating $124.2 billion in sales, an increase from $116.9 billion in 2023. The international segment also contributed, with Germany and the United Kingdom reporting sales of $12.1 billion and $9.6 billion, respectively.
Cash Flow and Investments
Walgreens Boots Alliance reported net cash provided by operating activities of $1.018 billion in 2024, down from $2.258 billion in 2023. The company’s capital expenditures amounted to $1.381 billion, reflecting a reduction in investment as part of its cost management efforts.
| Cash Flow Metrics | 2024 (in millions) | 2023 (in millions) |
|---|---|---|
| Net Cash Provided by Operating Activities | $1,018 | $2,258 |
| Capital Expenditures | $1,381 | $2,117 |
Debt and Financing Activities
As of August 31, 2024, Walgreens Boots Alliance had total long-term debt of $8.044 billion, slightly down from $8.145 billion in 2023. The company has actively managed its debt, including the issuance of $750 million in 8.125% notes due in 2029 during the fiscal year.
The future maturities of the company's debt as of August 31, 2024, are as follows:
| Year | Amount (in millions) |
|---|---|
| 2025 | $1,505 |
| 2026 | $2,838 |
| 2027 | $1,835 |
| 2028 | $1 |
| 2029 | $751 |
| Later | $2,651 |
| Total | $9,581 |
Market Position and Challenges
Walgreens Boots Alliance's market position has been challenged by various factors, including increased competition in the pharmacy sector, evolving healthcare landscape, and the integration of recent acquisitions. The company continues to adapt its strategy to address these challenges, focusing on improving operational efficiencies and enhancing customer offerings.
In summary, Walgreens Boots Alliance's financial and operational landscape as of 2024 reflects both the ongoing challenges and strategic adjustments necessary to maintain its position in the competitive healthcare market.
A Who Owns Walgreens Boots Alliance, Inc. (WBA)
Major Shareholders
As of 2024, the ownership structure of Walgreens Boots Alliance, Inc. (WBA) consists of a mix of institutional investors, individual shareholders, and company insiders. The following table summarizes the major shareholders by percentage ownership:
| Shareholder Type | Shareholder Name | Ownership Percentage |
|---|---|---|
| Institutional Investors | The Vanguard Group, Inc. | 8.61% |
| Institutional Investors | BlackRock, Inc. | 7.85% |
| Institutional Investors | State Street Corporation | 4.98% |
| Hedge Funds | Wellington Management Group LLP | 5.12% |
| Company Insiders | Roshak, John (CEO) | 0.04% |
| Company Insiders | Cohen, Richard (CFO) | 0.03% |
| Other | Individual Investors | 73.33% |
Recent Stock Performance
Walgreens Boots Alliance has seen fluctuations in its stock price throughout 2024. As of August 31, 2024, the stock was trading at approximately $12 per share, reflecting a significant decline from its previous year.
| Period | Stock Price ($) | Market Capitalization ($ Billion) |
|---|---|---|
| Q1 2024 | 12.50 | 10.79 |
| Q2 2024 | 11.75 | 10.19 |
| Q3 2024 | 11.00 | 9.49 |
| Q4 2024 | 12.00 | 10.32 |
Financial Overview
Walgreens Boots Alliance reported the following key financial metrics for the fiscal year ending August 31, 2024:
| Metric | Value |
|---|---|
| Total Sales | $147.66 Billion |
| Gross Profit | $26.52 Billion |
| Net Loss | $(8.64 Billion) |
| Adjusted Net Earnings | $2.49 Billion |
| Operating Loss | $(14.08 Billion) |
| Cash Flow from Operating Activities | $1.02 Billion |
Debt and Obligations
As of August 31, 2024, Walgreens Boots Alliance had a total long-term debt of approximately $8.04 billion. The company has been actively managing its debt levels and reducing overall liabilities.
| Debt Type | Amount ($ Billion) |
|---|---|
| Long-term Debt | 8.04 |
| Short-term Debt | 1.51 |
| Total Debt | 9.55 |
Conclusion of Ownership Structure
Walgreens Boots Alliance's ownership is predominantly held by institutional investors, with significant stakes from major asset management firms. The company's financial performance in 2024 has been challenging, reflecting broader market pressures and operational hurdles.
Walgreens Boots Alliance, Inc. (WBA) Mission Statement
Walgreens Boots Alliance, Inc. is committed to creating more joyful lives through better health. This mission encompasses the company's dedication to providing high-quality pharmacy and healthcare services across its extensive network of retail and digital platforms. The company aims to improve access to healthcare while ensuring a focus on customer convenience and satisfaction.
Mission Statement Overview
As of 2024, Walgreens Boots Alliance emphasizes its role in the healthcare ecosystem by integrating pharmacy services with broader health and wellness offerings. The company seeks to enhance the quality of care and outcomes while lowering overall costs through coordinated efforts with health plans and health systems.
Strategic Objectives
- To enhance customer access to healthcare services.
- To deliver high-quality health and beauty products.
- To leverage digital platforms for greater convenience.
- To engage underserved communities for improved health outcomes.
- To promote sustainability and corporate responsibility.
Financial Performance Metrics
Walgreens Boots Alliance has reported significant financial metrics that reflect its mission-driven approach. Below is a summary of key financial figures for fiscal 2024:
| Metric | Fiscal 2024 (in millions) | Fiscal 2023 (in millions) | Fiscal 2022 (in millions) |
|---|---|---|---|
| Sales | $147,658 | $139,081 | $132,703 |
| Gross Profit | $26,524 | $27,072 | $28,265 |
| Selling, General and Administrative Expenses | $28,113 | $34,205 | $27,295 |
| Net Loss Attributable to WBA | $(8,636) | $(3,080) | $4,337 |
| Adjusted Net Earnings | $2,491 | $3,439 | $4,360 |
| Adjusted Diluted Earnings per Share | $2.88 | $3.98 | $5.04 |
Customer Engagement and Loyalty Programs
Walgreens Boots Alliance actively engages its customer base through various loyalty programs. As of August 31, 2024, the number of members in the myWalgreens loyalty program has reached approximately 124 million, reflecting the company’s commitment to enhancing customer experience and retention.
Healthcare Integration
The company has expanded its healthcare services significantly, with a focus on value-based care. This includes partnerships with health plans and systems to improve patient engagement, especially in underserved areas. The integration of digital platforms such as Walgreens Find Care enhances accessibility to healthcare services.
Market Presence and Workforce
Walgreens Boots Alliance operates approximately 12,500 locations across the U.S., Europe, and Latin America, employing around 312,000 people. This extensive network enables the company to serve millions of customers effectively and efficiently.
Commitment to Sustainability
The company's sustainability strategy focuses on creating healthy communities and a healthier planet. Walgreens Boots Alliance is recognized for its efforts in environmental stewardship and social responsibility, having been named to the Dow Jones Sustainability Indices for four consecutive years as of 2023.
Conclusion
Walgreens Boots Alliance continues to evolve its mission to create more joyful lives through better health, demonstrating significant financial performance and a commitment to customer engagement, healthcare integration, and sustainability.
How Walgreens Boots Alliance, Inc. (WBA) Works
Company Overview
Walgreens Boots Alliance, Inc. operates through three primary segments: U.S. Retail Pharmacy, International, and U.S. Healthcare. The company is involved in retail drugstore operations, health and wellness services, pharmaceutical distribution, and specialty pharmacy services.
Financial Performance
For the fiscal year ended August 31, 2024, Walgreens Boots Alliance reported significant financial metrics:
| Metric | 2024 | 2023 | 2022 |
|---|---|---|---|
| Sales (in millions) | $147,658 | $139,081 | $132,703 |
| Gross Profit (in millions) | $26,524 | $27,072 | $28,265 |
| Selling, General and Administrative Expenses (in millions) | $28,113 | $34,205 | $27,295 |
| Impairment of Goodwill (in millions) | $12,701 | $0 | $0 |
| Operating Income (Loss) (in millions) | $(14,076) | $(6,882) | $1,387 |
| Net (Loss) Earnings (in millions) | $(8,636) | $(3,080) | $4,337 |
| Net (Loss) Earnings per Share | $(10.01) | $(3.57) | $5.02 |
Segment Performance
The company’s operations are broken down into three segments, each contributing to overall sales and profit:
| Segment | Sales (in millions) | Operating Income (Loss) (in millions) |
|---|---|---|
| U.S. Retail Pharmacy | $115,778 | $(385) |
| International | $23,552 | $682 |
| U.S. Healthcare | $8,345 | $(14,241) |
Cash Flow and Debt Management
Walgreens Boots Alliance has focused on improving its cash flow and reducing its debt load:
| Cash Flow Metrics | 2024 | 2023 | 2022 |
|---|---|---|---|
| Net Cash Provided by Operating Activities (in millions) | $1,000 | $2,300 | $3,900 |
| Net Cash Used for Investing Activities (in millions) | $(1,900) | $(3,100) | $(1,100) |
| Total Long-term Debt (in millions) | $8,044 | $8,145 | Not provided |
Operational Changes and Strategic Initiatives
In 2024, the company announced a Footprint Optimization Program to close approximately 900 to 1,000 underperforming stores by the end of fiscal 2027. This program aims to enhance operational efficiency and adapt to changing consumer behaviors.
Market Position and Competitive Landscape
Walgreens Boots Alliance continues to face challenges in the retail pharmacy landscape, including competitive pressures and evolving consumer preferences, impacting sales and profit margins.
Conclusion
The company's financial results indicate a challenging year, with significant impairments and operating losses, particularly in the U.S. Healthcare segment. Efforts to optimize operations and manage debt will be crucial for future performance.
How Walgreens Boots Alliance, Inc. (WBA) Makes Money
Revenue Streams
Walgreens Boots Alliance, Inc. (WBA) generates revenue through multiple segments, primarily through U.S. Retail Pharmacy, International operations, and U.S. Healthcare services.
Financial Performance Overview
For fiscal year 2024, WBA reported the following financial metrics:
| Metric | Fiscal Year 2024 | Fiscal Year 2023 | Fiscal Year 2022 |
|---|---|---|---|
| Sales | $147,658 million | $139,081 million | $132,703 million |
| Gross Profit | $26,524 million | $27,072 million | $28,265 million |
| Selling, General and Administrative Expenses | $28,113 million | $34,205 million | $27,295 million |
| Operating (Loss) Income | $(14,076) million | $(6,882) million | $1,387 million |
| Net (Loss) Earnings | $(15,448) million | $(3,528) million | $4,065 million |
U.S. Retail Pharmacy Segment
The U.S. Retail Pharmacy segment is the largest contributor to WBA's revenue, including sales from retail drugstores, health services, and specialty pharmacy services.
In fiscal 2024, the U.S. Retail Pharmacy segment reported:
| Metric | Fiscal Year 2024 | Fiscal Year 2023 |
|---|---|---|
| Sales | $115,778 million | $110,314 million |
| Gross Profit | $20,736 million | $22,115 million |
| Selling, General and Administrative Expenses | $21,334 million | $27,674 million |
| Operating (Loss) Income | $(385) million | $(5,307) million |
International Segment
The International segment consists of pharmacy-led health and beauty retail businesses outside the U.S. and pharmaceutical wholesaling in Germany. In fiscal 2024, the International segment reported:
| Metric | Fiscal Year 2024 | Fiscal Year 2023 |
|---|---|---|
| Sales | $12,067 million | $11,211 million |
| Gross Profit | Data not available | Data not available |
| Selling, General and Administrative Expenses | Data not available | Data not available |
U.S. Healthcare Segment
The U.S. Healthcare segment includes VillageMD and Shields, focusing on value-based care and pharmacy integration. For fiscal 2024, the U.S. Healthcare segment reported:
| Metric | Fiscal Year 2024 | Fiscal Year 2023 |
|---|---|---|
| Sales | $8,345 million | $6,570 million |
| Adjusted Operating Loss | $(134) million | $(566) million |
| Adjusted EBITDA | $66 million | $(376) million |
Market Trends and Sales Drivers
In fiscal 2024, WBA filled approximately 796 million prescriptions, with 1.2 billion adjusted to 30-day equivalents. Pharmacy sales represented 76.8% of total segment sales, benefiting from branded drug inflation and effective pharmacy services execution.
Retail sales, however, faced challenges, decreasing by 4.6%, influenced by a weaker retail environment and lower seasonal sales.
Cost Structure and Profitability
WBA's cost structure is significantly impacted by selling, general, and administrative expenses. In fiscal 2024, these expenses accounted for 19.0% of total sales, reflecting a decrease from prior periods due to cost-saving initiatives but still impacted by ongoing inflation and market pressures.
Debt and Financial Obligations
As of August 31, 2024, WBA reported a net loss of $15.4 billion, with substantial liabilities including a $6.6 billion provision for opioid-related claims, expected to be settled over the next 15 years. The company also reduced its net debt by nearly $2 billion during fiscal 2024.
Conclusion
Walgreens Boots Alliance, Inc. employs a diversified approach to revenue generation through its retail pharmacy, international operations, and healthcare services, while navigating significant challenges in profit margins and market dynamics.
Walgreens Boots Alliance, Inc. (WBA) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support